NYSE: CNCCentene Corp Stock
$26.93-0.14 (-0.52%)
Updated Aug 14, 2025
Shares of health insurers are... find out Why CNC Price Moved with a free WallStreetZen account
Why Price MovedCNC Price
$26.93
Fair Value Price
N/A
Market Cap
$13.23B
52 Week Low
$25.08
52 Week High
$80.59
P/E
6.54x
P/B
0.48x
P/S
0.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$178.19B
Earnings
$2.05B
Gross Margin
8.9%
Operating Margin
1.94%
Profit Margin
1.2%
Debt to Equity
2.15
Operating Cash Flow
$2B
Beta
0.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNC Overview
Centene Corporation provides programs and services to government-sponsored healthcare programs, focusing on under-insured and uninsured individuals. Centene serves about 24 million members, mostly in Medicaid, Medicare, and other plans, including Tricare, correctional facility, and international plans. Formerly known as Managed Health Services, Centene was founded in 1984 and is based in St. Louis, MO.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
B
CNC
Ranked#8 of 10
Ranked#8 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $66.73 | B | |
| $14.82 | C | |
| $295.43 | C |
Be the first to know about important CNC news, forecast changes, insider trades & much more!
CNC News
Overview
Due Diligence Score
–
Industry Average (37)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNC is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNC is good value based on its earnings relative to its share price (6.54x), compared to the US market average (36.29x)
P/E vs Market Valuation
CNC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CNC due diligence checks available for Premium users.
Valuation
CNC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
6.54x
Industry
13.12x
Market
36.29x
CNC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CNC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CNC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
1.76x
CNC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNC's financial health
Profit margin
Revenue
$48.7B
Net Income
-$253.0M
Profit Margin
-0.5%
CNC's Earnings (EBIT) of $3.45B... subscribe to Premium to read more.
Interest Coverage Financials
CNC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$86.4B
Liabilities
$58.9B
Debt to equity
2.15
CNC's short-term assets ($40.39B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNC's short-term assets ($40.39B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CNC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.8B
Investing
-$899.0M
Financing
-$1.2B
CNC's operating cash flow ($1.73B)... subscribe to Premium to read more.
Debt Coverage Financials
CNC vs Healthcare Plan Stocks
Centene Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.